STOCKHOLM, July 24, 2017 /PRNewswire/ -- Fluicell AB, a pioneering high-tech company in single-cell biology, is extremelydelighted to announce the issuance of US Patent No 9,6719,671,366, entitled "Pipettes, methods of use, and methods of stimulating an object of interest", by the USPTO.
This is the third patent issued to Fluicell AB, representing a continued advancement
This approval gives further recognition to the Fluicell team as innovation leaders, and solution providers for cell biology research and discovery tools for the 21st century.
For further information, please visit us at fluicell.com or contact:
Victoire ViannayCEOTel: +46-725-65-42-05E-mail: email@example.com
Fluicell is an exciting Swedish high-tech company that brings inspiration and innovation to life science researchers around the globe. Fluicell provides innovative tools with outstanding performance, redefining approaches within; cell biology, bioprinting, and secondary drug screening and discovery. Fluicell strives for technology solutions which are environmentally friendly, sustainable, and that ultimately reduces costs, resource use, and animals. Fluicell's main target sectors include universities, the pharmaceutical industry, and national health laboratories.
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/fluicell-receives-a-new-patent-acceptance-for-the-biopen-system-300492711.html
Subscribe to our Free Newsletters!
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...
Ecchymosis is a flat, discolored patch of skin that occurs when there is bleeding underneath; it is ...
Age related macular degeneration is a disease of the elderly, wherein the macula or the central ...View All